Advertisement

Tardive dyskinesia: Out of the shadows

  • Robert A. Hauser
    Correspondence
    Corresponding author at: Parkinson's Disease and Movement Disorders Center, Departments of Neurology, Molecular Pharmacology and Physiology, Parkinson Foundation Center of Excellence, University of South Florida, 4001 E. Fletcher Ave, 6th Floor, Tampa, FL 33613, United States.
    Affiliations
    University of South Florida, Departments of Neurology, Molecular Pharmacology and Physiology, Tampa, FL, United States
    Search for articles by this author
  • Daniel Truong
    Affiliations
    The Truong Neurosciences Institute, Fountain Valley, CA, United States

    Department of Neurology, University of California, Riverside, CA, United States
    Search for articles by this author
Published:February 05, 2018DOI:https://doi.org/10.1016/j.jns.2018.02.009

      Abstract

      The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care. Tardive syndromes are defined as delayed onset, persistent movement disorders or sensory phenomena that occur in association with exposure to dopamine receptor blocking agents (DRBAs). Their underlying pathophysiology remains to be fully elucidated, but clinicians can conceptualize tardive syndromes as persistent dopamine supersensitivity states. Tardive syndromes can potentially cause distress, disfigurement, embarrassment, and dysfunction, and are often permanent. Therefore, practitioners who prescribe DRBAs should be aware of this potential, carefully assess the risk/benefit ratio when considering the use of these medications, and be sure that patients are appropriately informed. Patients on DRBAs should be monitored for the development of tardive syndromes, including through the use of regularly scheduled Abnormal Involuntary Movement Scale (AIMS) (or similar) examinations. Clinicians prescribing DRBAs should be familiar with the diagnosis and management of tardive syndromes, and be able to institute treatment or refer patients when treatment is appropriate. Future research may focus on the potential benefit of earlier introduction of VMAT2 inhibitors to delay onset or progression of tardive syndromes. More effective treatments are still needed, as are effective, well-tolerated antipsychotics that do not cause tardive syndromes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schönecker M.
        Paroxysmal dyskinesia as the effect of megaphen.
        Nervenarzt. 1957; 28: 550-553
        • Faurbye A.
        • Rasch P.J.
        • Petersen P.B.
        • Brandborg G.
        • Pakkenberg H.
        Neurological symptoms in pharmacotherapy of psychoses.
        Acta Psychiatr. Scand. 1964; 40: 10-27
        • Savitt D.
        • Jankovic J.
        Tardive syndromes.
        J. Neurol. Sci. 2018; (in this issue)https://doi.org/10.1016/j.jns.2018.02.005
        • Ford B.
        • Greene P.
        • Fahn S.
        Oral and genital tardive pain syndromes.
        Neurology. 1994; 44: 2115-2119
        • Frei K.
        • Truong D.
        • Fahn S.
        • Jankovic J.
        • Hauser R.A.
        The nosology of tardive syndromes.
        J. Neurol. Sci. 2018; (in this issue)https://doi.org/10.1016/j.jns.2018.02.008
        • Burt D.R.
        • Creese I.
        • Snyder S.H.
        Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.
        Science. 1977; 196: 326-328
        • Mahmoudi S.
        • Levesque D.
        • Blanchet P.J.
        Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.
        Mov. Disord. 2014; 29: 1125-1133
        • Levesque C.
        • Hernandez G.
        • Mahmoudi S.
        • Calon F.
        • Gasparini F.
        • Gomez-Mancilla B.
        • et al.
        Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
        Neuroscience. 2017; 361: 43-57
        • Teo J.T.
        • Edwards M.J.
        • Bhatia K.
        Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.
        Mov. Disord. 2012; 27: 1205-1215
        • Guy W.
        • National Institute of Mental H, Psychopharmacology Research B, Early Clinical Drug Evaluation P
        ECDEU Assessment Manual for Psychopharmacology.
        U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD1976
        • Carbon M.
        • Hsieh C.H.
        • Kane J.M.
        • Correll C.U.
        Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis.
        J. Clin. Psychiatry. 2017; 78e264-e78
        • Woods S.W.
        • Morgenstern H.
        • Saksa J.R.
        • Walsh B.C.
        • Sullivan M.C.
        • Money R.
        • et al.
        Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
        J. Clin. Psychiatry. 2010; 71: 463-474
        • Munoz R.A.
        American psychiatric association practice guidelines for the treatment of psychiatric disorders: compendium 2000.
        Am. J. Psychiatr. 2002; 159: 1066
        • Solmi M.
        • Pigato G.
        • Kane J.M.
        • Correll C.U.
        Clinical risk factors for the development of tardive dyskinesia.
        J. Neurol. Sci. 2018; (in this issue)https://doi.org/10.1016/j.jns.2018.02.012
        • Hauser R.A.
        • Factor S.A.
        • Marder S.R.
        • Knesevich M.A.
        • Ramirez P.M.
        • Jimenez R.
        • et al.
        KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of Valbenazine for tardive dyskinesia.
        Am. J. Psychiatry. 2017; 174: 476-484
        • Fernandez H.H.
        • Factor S.A.
        • Hauser R.A.
        • Jimenez-Shahed J.
        • Ondo W.G.
        • Jarskog L.F.
        • et al.
        Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study.
        Neurology. 2017; 88: 2003-2010
        • Macerollo A.
        • Deuschl G.
        Deep brain stimulation for tardive dyskinesia: systematic review and meta-analysis.
        J. Neurol. Sci. 2018; (in this issue)https://doi.org/10.1016/j.jns.2018.02.013